DelveInsight’s, “Stargardt Disease Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Stargardt Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Stargardt Disease Pipeline Report

• DelveInsight’s Stargardt Disease pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
• The leading companies working in the Stargardt Disease Market include IVERIC bio, Nanoscope Therapeutics, Alkeus Pharmaceuticals, Kubota Vision, Astellas Pharma, Stargazer Pharmaceuticals Inc., Belite Bio, ProQR Therapeutics, ReVision Therapeutics, and others.
• Promising Stargardt Disease Pipeline Therapies in the various stages of development include tinlarebant, Emixustat, OCU410ST, STG-001, Zimura, ALK-001 MA09-hRPE, and others.
• September 2023: Ocugen announced a study of phase 1 & 2 clinical trials for OCU41OST. This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.
• September 2023: Nanoscope Therapeutics Inc. announced a study of phase 2 clinical trials for Gene Therapy-vMCO-010. The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease.

 

Request a sample and discover the recent advances in Stargardt Disease Treatment Drugs @ Stargardt Disease Pipeline Report

 

In the Stargardt Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Stargardt Disease Overview

Stargardt disease is caused by inheritance of a faulty gene: the ABCA4 gene. Genes are in pairs, one inherited from the father and one from the mother. If abnormal ABCA4 genes are inherited from both parents, then the disease will occur. Because of these abnormal genes, a build-up of waste material from metabolism called lipofuscin occurs in the retina.

 

Find out more about Stargardt Disease Therapeutics Assessment @ Stargardt Disease Preclinical and Discovery Stage Products

 

Stargardt Disease Emerging Drugs Profile

• Tinlarebant: Belite Bio

 

Stargardt Disease Pipeline Therapeutics Assessment

There are approx. 18+ key companies which are developing the Stargardt Disease therapies. The Stargardt Disease companies which have their Stargardt disease drug candidates in the most advanced stage, i.e. Phase III include, Belite Bio.

 

Learn more about the emerging Stargardt Disease Pipeline Therapies @ Stargardt Disease Clinical Trials Assessment

 

Scope of the Stargardt Disease Pipeline Report

• Coverage- Global
• Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Stargardt Disease Companies- IVERIC bio, Nanoscope Therapeutics, Alkeus Pharmaceuticals, Kubota Vision, Astellas Pharma, Stargazer Pharmaceuticals Inc., Belite Bio, ProQR Therapeutics, ReVision Therapeutics, and others.
• Stargardt Disease Pipeline Therapies- tinlarebant, Emixustat, OCU410ST, STG-001, Zimura, ALK-001 MA09-hRPE, and others.

 

Dive deep into rich insights for new drugs for Stargardt Disease Treatment, Visit @ Stargardt Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Stargardt disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Stargardt disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tinlarebant: Belite Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Retinol deuterated: Alkeus Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. REV 0100: ReVision Therapeutics
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Stargardt disease Key Companies
24. Stargardt disease Key Products
25. Stargardt disease -Unmet Needs
26. Stargardt disease -Market Drivers and Barriers
27. Stargardt disease -Future Perspectives and Conclusion
28. Stargardt disease Analyst Views
29. Stargardt disease Key Companies
30. Appendix

 

For further information on the Stargardt Disease Pipeline therapeutics, reach out to Stargardt Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking